The present findings indicate that our NK cell expansion protocol combined with PD1 blockade may have a great clinical potential for cancer immunotherapies, and that the protocol provides a simple and efficient system for the therapeutical production of NK cells. This evidence concerns the gene PDCD1 and cancer.